Geburtshilfe Und Frauenheilkunde最新文献

{"title":"Letter to the editor on \"Effects of Systematically Guided vs. Self-Directed Laparoscopic Box Training on Learning Performances\".","authors":"Florian Recker, Ricarda Neubauer","doi":"10.1055/a-2539-5940","DOIUrl":"10.1055/a-2539-5940","url":null,"abstract":"","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"548-550"},"PeriodicalIF":2.6,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update Breast Cancer 2024 Part 2 - Patients with Early Stage Breast Cancer.","authors":"Wolfgang Janni, Hans-Christian Kolberg, Andreas D Hartkopf, Tanja N Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A Fasching, Christian Jackisch, Frederik Marme, Manuel Hörner, Katharina Keller, Chloë Goossens, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Michael P Lux, Maggie Banys-Paluchowski, Achim Wöckel, Nadia Harbeck, Elmar Stickeler, Rupert Bartsch, Bahriye Aktas, Andreas Schneeweiss, Johannes Ettl, Florin-Andrei Taran, Diana Lüftner, Rachel Würstlein, Julia C Radosa","doi":"10.1055/a-2533-2783","DOIUrl":"10.1055/a-2533-2783","url":null,"abstract":"<p><p>This review summarizes the latest developments for the treatment of patients with early-stage breast cancer. Most of the clinically relevant changes were the result of using immune checkpoint inhibitors to treat patients with triple-negative breast cancer (TNBC) and CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative (HRpos/HER2neg) tumors and a high risk of recurrence. Recent studies are presenting more and more data with long follow-up times and integrating translational analyses to evaluate new biomarkers such as circulating tumor DNA (ctDNA). This review article summarizes the latest developments published in recent months and puts the findings in context.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 5","pages":"493-506"},"PeriodicalIF":2.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12081099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Vaccine Effectiveness in SARS-CoV-2-Infected Pregnant Women with Gestational Diabetes Mellitus: Results from a Multicenter Registry-Based Prospective Cohort Study in Germany.","authors":"Eike A Strathmann, Katharina S Weber, Babett Ramsauer, Dietmar Schlembach, Janine Zöllkau, Ute M Schaefer-Graf, Sophia Ajouby, Kristin Andresen, Michael K Bohlmann, Iris Dressler-Steinbach, Antonella Iannaccone, Peter Jakubowski, Mirjam Kunze, Bettina Kuschel, Nadine Mand, Mandy Mangler, Valerie Meister, Kathleen M Oberste, Katharina Rathberger, Kristin Reinhardt, Lydia Remtisch, Linda Wegner, Katharina Weizsäcker, Feline Wowretzko, Mario Rüdiger, Ulrich Pecks, Helmut J Kleinwechter","doi":"10.1055/a-2597-8003","DOIUrl":"10.1055/a-2597-8003","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1055/a-2576-6293.].</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 10","pages":"1102"},"PeriodicalIF":1.9,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517769/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine Effectiveness in SARS-CoV-2-Infected Pregnant Women with Gestational Diabetes Mellitus: Results from a Multicenter Registry-Based Prospective Cohort Study in Germany.","authors":"Eike A Strathmann, Katharina S Weber, Babett Ramsauer, Dietmar Schlembach, Janine Zöllkau, Ute M Schaefer-Graf, Sophia Ajouby, Kristin Andresen, Michael K Bohlmann, Iris Dressler-Steinbach, Antonella Iannaccone, Peter Jakubowski, Mirjam Kunze, Bettina Kuschel, Nadine Mand, Mandy Mangler, Valerie Meister, Kathleen M Oberste, Katharina Rathberger, Kristin Reinhardt, Lydia Remtisch, Linda Wegner, Katharina Weizsäcker, Feline Wowretzko, Mario Rüdiger, Ulrich Pecks, Helmut J Kleinwechter","doi":"10.1055/a-2576-6293","DOIUrl":"10.1055/a-2576-6293","url":null,"abstract":"<p><p><b>Introduction</b> COVID-19 in pregnancy is associated with increased maternal and neonatal morbidity and mortality. The aim of our study was to investigate the effectiveness of COVID-19 vaccination in SARS-CoV-2-infected pregnant women with focus on women with gestational diabetes mellitus on pregnancy outcomes. <b>Patients and Methods</b> COVID-19 Obstetric and Neonatal Outcome study is a multicenter prospective observational study which registered SARS-CoV-2-infected pregnant women from April 2020 to December 2022. In March 2021, the study was complemented by the SATELLITES study which recruited vaccinated women until September 2023. Primary composite maternal and neonatal endpoints were defined. Multivariate adjusted logistic regression analysis was performed to evaluate the impact of vaccination on pregnancy outcomes. Vaccine effectiveness was defined as (1-adjusted odds ratio)*100. <b>Results</b> We registered 10 386 pregnant women, 6112 of whom were analyzed. 30% of women were vaccinated against COVID-19. Vaccination in women with gestational diabetes mellitus was associated with a vaccine effectiveness of 75% (95% CI: 16 - 93), depending on the predominant virus variant, and of 67% in the total cohort (95% CI: 36 - 83). No statistically significant difference was found in vaccine effectiveness with regards to perinatal outcomes of women with gestational diabetes mellitus (16%; 95% CI -58 - 55) but there was an impact in the total cohort (26%; 95% CI 8 - 94). <b>Conclusion</b> For pregnant women with gestational diabetes mellitus who were infected with SARS-CoV-2, at least one vaccination against COVID-19 before or during pregnancy was independently associated with a milder course of COVID-19 in mothers compared to no vaccination. We found no evidence of improved perinatal outcomes. The data emphasize the benefits of vaccination before or during pregnancy.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 10","pages":"1090-1102"},"PeriodicalIF":1.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145291780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Congenital Imprinting Diseases: Aetiology, Pre- and Perinatal Manifestations, Diagnosis and Care of Affected Families and Pregnancies.","authors":"Thomas Eggermann, Karl Oliver Kagan, Andreas Dufke","doi":"10.1055/a-2567-3504","DOIUrl":"10.1055/a-2567-3504","url":null,"abstract":"<p><p>Congenital Imprinting Disorders (ImpDis) are caused by abnormal expression of parentally imprinted genes. They are characterized by disturbances of imprinting marks which are a specific type of epigenetic signatures and occur either sporadic or familial. So far, twelve ImpDis have been identified, eight of them manifest prenatally or in the neonate period. With exception of abdominal wall defects, ImpDis are rarely associated with major malformations, but predominant early manifestations are disturbed pre- and/or postnatal growth, muscular hypotonia, neonatal feeding difficulties and metabolic/hormonal dysfunction. With few exceptions prenatal clinical features of ImpDis are unspecific and manifest only in the late second or third trimester. In some ImpDis, behavioural, developmental, and neurological symptoms might emerge, and in single ImpDis there is a higher risk of cancer in childhood. Prenatal diagnosis plays a crucial role in appropriate pregnancy management and initial care of the newborn, which in turn has positive impact on the life-long outcome of the patient. Furthermore, the diagnosis of ImpDis is relevant for the prevention of pregnancy risks such as preeclampsia and possible reproductive problems in future pregnancies and other family members. Genetic analysis is not straightforward, and imprinting disturbances may escape both DNA sequencing analysis and (molecular-)cytogenetic diagnostics. After introducing the topic with a case report, this review focuses on the recognition of ImpDis including maternal and family history, exogeneous and genetic risk factors, fetal imaging, and genetic findings as well as interdisciplinary care and treatment approaches in the management and decision making of affected families and pregnancies.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 11","pages":"1141-1149"},"PeriodicalIF":2.6,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12591832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145481347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant Targeted Treatment of Early Hormone Receptor-positive HER2-negative Breast Cancer: Olaparib, Abemaciclib or Ribociclib - Which One, How and For Whom?","authors":"Stefan Lukac, Kerstin Pfister, Henning Schäffler, Elena Leinert, Angelina Fink, Brigitte Rack, Visnja Fink, Wolfgang Janni, Sabine Heublein","doi":"10.1055/a-2562-8469","DOIUrl":"10.1055/a-2562-8469","url":null,"abstract":"<p><p>With around 70000 new cases every year, breast cancer (BC) continues to be the most prevalent form of cancer. Hormone receptor-positive, HER2-negative (HR+/HER2-) BC is the most common type and accounts for around 70% of cases of early BC (eBC). The development of new drugs in recent years has significantly improved the survival of patients with eBC. Alongside established endocrine therapy (ET) options such as tamoxifen, aromatase inhibitors (AI), and GnRH analogs, additional treatment options such as CDK 4/6 inhibitors (abemaciclib and ribociclib) and the PARP inhibitor (olaparib) are now also available. To facilitate their use in clinical practice, this article provides a summary of the current information on the use of these drugs in clinical practice. Abemaciclib was approved for the adjuvant treatment of HR+/HER2- eBC in cases with positive lymph node involvement in 2022. The MonarchE trial showed that the addition of abemaciclib to ET improved invasive disease-free survival (iDFS) after 5 years by around 7.6% in patients with a high risk of recurrence. Ribociclib, another CDK4/6 inhibitor, was recently approved based on the results of the NATALEE trial. When combined with non-steroidal AIs, ribociclib showed a significant iDFS benefit of 4.9% after 4 years in node-positive and node-negative patients with a high risk of recurrence. The PARP inhibitor olaparib may be used to treat patients with BRCA germline mutation and HR+/HER2- eBC and a high risk of recurrence (CPS-EG score ≥ 3). The OlympiA approval study showed an iDFS benefit of 7.3% after four years and a benefit of 3.4% for overall survival. In summary, targeted therapies are expanding the range of adjuvant treatment options for patients with HR+/HER2- eBC and a higher risk of recurrence. Treating physicians are increasingly facing the challenge of choosing the optimal therapy for their patients. To do so, it is essential to carefully weigh up potential side effects against the expected benefit of treatment on a case-by-case basis.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 6","pages":"590-598"},"PeriodicalIF":2.4,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study.","authors":"Constantin Pixberg, Christian Maurer, Katharina Smetanay, Luise Straßl, Mario Hlevnjak, Marc Zapatka, Celina V Wagner, Haniyeh Yazdanparast, Johanna Kurzawa, Vanessa Erben, Fangyoumin Feng, Chen Hong, Daniel Hübschmann, Lars Buschhorn, Jan Philip Suppelna, Laura Michel, Sabine Heublein, Carlo Fremd, Oliver Zivanovic, Peter Sinn, Albrecht Stenzinger, Renate Haidinger, Eva Schumacher-Wulf, Nina Ditsch, Sibylle Loibl, Stefan Fröhling, Theresa Link, Pauline Wimberger, Jens-Uwe Blohmer, Hanna Huebner, Peter A Fasching, Wolfgang Janni, Richard F Schlenk, Verena Thewes, Peter Lichter, Andreas Schneeweiss","doi":"10.1055/a-2557-1876","DOIUrl":"10.1055/a-2557-1876","url":null,"abstract":"<p><strong>Background: </strong>As part of the COGNITION diagnostic registry program, residual tumor material after neoadjuvant therapy (NAT) of patients with early breast cancer (eBC), who are still at high-risk for relapse after NAT, is analyzed by next generation sequencing to identify biomarkers and actionable alterations. This strategy aims to stratify patients for subsequent genomics-guided therapies to reduce the significant risk of metastatic dissemination and hence to improve disease-free survival.</p><p><strong>Patients and methods: </strong>COGNITION-GUIDE is a multicenter umbrella phase-II-trial to translate molecular biomarker profiles generated in the COGNITION platform into six molecular-guided post-neoadjuvant therapeutic options in addition to standard-of-care treatment. Patients can be allocated toimmune checkpoint inhibition (PD-L1-antibody),PI3K inhibition,AKT inhibition,PARP inhibition,anti-Trop-2 antibody-drug-conjugate,HER2 inhibition or, in case of missing biomarkers, to observation for 12 months.The primary endpoint is invasive disease-free survival (IDFS) four years after surgery. Secondary endpoints include IDFS in each study arm separately, distant disease-free survival, overall survival and safety. 240 patients will be enrolled within four years.</p><p><strong>Conclusions: </strong>The COGNITION-GUIDE trial, which was activated in June 2023 and will recruit in different centers in Germany, empowers a risk-adapted, biomarker-guided therapy escalation algorithm in eBC patients who are still at high risk of metastasis.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 6","pages":"611-619"},"PeriodicalIF":2.4,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect Treatment Comparison between Ribociclib Combined with Non-Steroidal Aromatase Inhibitors and Ovarian Function Suppression vs. Tamoxifen in Premenopausal Women with Early Breast Cancer.","authors":"Diana Lüftner, Maggie Banys-Paluchowski, Andreas D Hartkopf, Manuel Hörner, Wolfgang Janni, Dagmar Langanke, Volkmar Müller, Andreas Schneeweiss, Marcus Schmidt, Marc Thill, Michael Untch, Achim Wöckel, Lukas Höllrich, Julia Kreuzeder, Almuth Marx, Julia Meinzinger, Hanna Regus-Leidig, Christian Roos, Hien Wohlgemuth, Stephanie Sussmann, Peter A Fasching","doi":"10.1055/a-2561-6640","DOIUrl":"10.1055/a-2561-6640","url":null,"abstract":"<p><strong>Background: </strong>This study provides an indirect treatment comparison of ribociclib combined with non-steroidal aromatase inhibitors and ovarian function suppression (ribociclib + NSAI + OFS) vs. a frequently used treatment option in German clinical routine (tamoxifen ± OFS) in premenopausal patients with HR-positive (HR+), HER2-negative (HER2-) early breast cancer (BC).</p><p><strong>Material and methods: </strong>Data on premenopausal women treated with ribociclib and tamoxifen were derived from the NATALEE clinical trial (NCT03701334) and the retrospective German data collection CLEAR-B, respectively. NATALEE trial eligibility criteria were applied to the CLEAR-B dataset. Standardized mortality ratio weights were used for propensity score (PS) adjustment to balance study populations. All hazard ratios (HR) were calculated based on a 4-year-observation period for both treatment arms. Effectiveness endpoints comprised invasive and distant disease-free survival (iDFS, dDFS), recurrence-free survival (RFS), and overall survival (OS). Safety-related endpoints were treatment termination (TT) and toxicity-related TT (TTtox). For safety comparisons, the ribociclib arm was divided into groups that discontinued ribociclib + NSAI + OFS or ribociclib only.</p><p><strong>Results: </strong>Significant beneficial effects favoring ribociclib + NSAI + OFS (n = 1115) over tamoxifen ± OFS (n = 822) were observed for all effectiveness outcomes (iDFS [HR = 0.5 (95% CI 0.35; 0.71); p < 0.01]; dDFS [HR = 0.52 (95% CI 0.35; 0.77); p = 0.01], RFS [HR = 0.42 (95% CI 0.29; 0.62); p < 0.01], OS [HR = 0.34 (95% CI 0.18; 0.63); p = 0.01]) during the 4-year-observation period. The effect of early treatment discontinuation showed no significant differences between ribociclib + NSAI + OFS and tamoxifen ± OFS (TT-a: HR = 1.2 [95% CI: 0.71; 2.01], p = 0.48; TTtox-a: HR = 0.54 [95% CI 0.22; 1.30], p = 0.23).</p><p><strong>Conclusion: </strong>In this retrospective analysis, ribociclib + NSAI + OFS demonstrated advantages across all effectiveness endpoints, including OS, in premenopausal women with HR+, HER2- early BC, without increasing overall treatment discontinuation rates compared to tamoxifen ± OFS.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 6","pages":"599-610"},"PeriodicalIF":2.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12158542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, June 2024).","authors":"Markus Wallwiener, Marco Johannes Battista, Eike-Christian Burandt, Wolfgang Cremer, Gerlinde Egerer, Mathias K Fehr, Markus Follmann, Paul Gass, Heidemarie Haase, Philipp Harter, Florian Heitz, Simone Hettmer, Lars-Christian Horn, Ingolf Juhasz-Böss, Karin Kast, Günther Köhler, Thomas Kröncke, Katja Lindel, Alexander Mustea, Jan Philipp Novotny, Edgar Petru, Peter Reichardt, Kerstin Rhiem, Hans-Georg Strauß, Clemens Tempfer, Falk C Thiel, Uwe Andreas Ulrich, Thomas Vogl, Dirk Vordermark, Dominik Denschlag","doi":"10.1055/a-2496-2591","DOIUrl":"10.1055/a-2496-2591","url":null,"abstract":"<p><p><b>Purpose</b> This is an official, recently updated guideline published and coordinated by the German Society of Gynecology and Obstetrics ( <i>Deutsche Gesellschaft für Gynäkologie und Geburtshilfe</i> , DGGG) together with the Austrian Society of Gynecology and Obstetrics ( <i>Österreichische Gesellschaft für Gynäkologie und Geburtshilfe</i> , OEGGG) and the Swiss Society of Gynecology and Obstetrics ( <i>Schweizerische Gesellschaft für Gynäkologie und Geburtshilfe</i> , SGGG) as part of the guidelines program. Because of their rarity and heterogeneous histopathology, uterine sarcomas are challenging in terms of their clinical management, and treatment requires a multidisciplinary approach. <b>Methods</b> This S2k guideline was first published in 2015. The update published here is again the result of a structured consensus of a representative interdisciplinary group of mandate holders and experts who carried out a selective search of the literature on uterine sarcomas. Members of the participating professional societies achieved a formal consensus on recommendations and statements after a structured consensus process. <b>Recommendations</b> Recommendations were made about the epidemiology, classification, staging of uterine sarcomas, symptoms, general diagnostic workup, general pathology and genetic predisposition for uterine sarcomas, leiomyosarcomas, endometrial stromal sarcomas (low-grade and high-grade), undifferentiated uterine sarcomas, adenosarcomas, and rhabdomyosarcoma of the uterus in children and adolescents. The guideline also discusses the follow-up of uterine sarcomas, the management of morcellated uterine sarcomas, and the information provided to patients.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 4","pages":"378-394"},"PeriodicalIF":2.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11975451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Key Messages of the Iodine Deficiency Working Group (AKJ): Maternal Hypothyroxinemia Due to Iodine Deficiency and Endocrine Disruptors as Risks for Child Neurocognitive Development.","authors":"Rolf Grossklaus, Klaus-Peter Liesenkötter, Klaus Doubek, Henry Völzke, Roland Gaertner","doi":"10.1055/a-2505-1944","DOIUrl":"10.1055/a-2505-1944","url":null,"abstract":"<p><p>Iodine deficiency with the resultant maternal hypothyroxinemia and the effects of endocrine disruptors can, individually or together, have a negative effect on embryonic and fetal brain development. This is the conclusion of a recent review by the authors which examined and critically discussed a total of 279 publications from the past 30 years on the effects of mild to moderate iodine deficiency, reduced maternal thyroxine levels, and the influence of endocrine disruptors on child brain development during pregnancy. Adequate iodine intake is important for all women of childbearing age to prevent negative psychological and social consequences for their children. An additional threat to the thyroid hormone system is the ubiquitous exposure to endocrine disruptors, which can increase the impact of maternal iodine deficiency on the neurocognitive development of their offspring. Ensuring an adequate iodine intake is therefore not only crucial for healthy fetal and neonatal development in general, but could also prevent the potential effects of endocrine disruptors. Due to the current deficient iodine status of women of childbearing age and of children and adolescents in Germany and most European countries, urgent measures are needed to improve the iodine intake of the population. Therefore, in the opinion of the AKJ, young women of childbearing age should be instructed to take iodine supplements continuously for at least 3 months before conception and during pregnancy. In addition, detailed strategies for detecting and reducing exposure to endocrine disruptors in accordance with the \"precautionary principle\" should be urgently developed.</p>","PeriodicalId":12481,"journal":{"name":"Geburtshilfe Und Frauenheilkunde","volume":"85 8","pages":"796-809"},"PeriodicalIF":2.6,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12324869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}